---
layout: default
title: Semaglutide
parent: Model Prediction Only (L5)
nav_order: 625
evidence_level: L5
indication_count: 10
---

# Semaglutide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Semaglutide: From [Original Indication Not Documented] to Classic Stiff Person Syndrome

## One-Sentence Summary

> Semaglutide is a GLP-1 receptor agonist acting primarily on insulin secretion and appetite-regulation pathways (per the prediction rationale in this dataset); no original indication record is present in this evidence pack.
> The TxGNN model predicts it may be effective for **Classic Stiff Person Syndrome**, an anti-GAD65 autoimmune neuromuscular disorder,
> but currently **0 clinical trials** and **0 publications** support this specific pairing, and the evidence pack itself flags the mechanistic link as unsupported.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in this evidence pack (`original_indications` is empty; no ARTG licence records) |
| Predicted New Indication | Classic Stiff Person Syndrome |
| TxGNN Prediction Score | 98.64% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for semaglutide is not available as a standalone field in this dataset (`original_moa` = Data Gap). However, the prediction rationale embedded in the evidence pack characterises semaglutide as a **GLP-1 receptor agonist**, acting mainly on insulin secretion and appetite/satiety regulation — consistent with its established therapeutic class.

Classic Stiff Person Syndrome is an autoimmune neuromuscular disorder driven by anti-GAD65 antibodies affecting GABAergic neurotransmission. There is no structural or pharmacological overlap between this autoimmune/neurological mechanism and semaglutide's metabolic GLP-1 signalling pathway.

**This dataset's own rationale for the prediction is explicitly cautionary**: it states that the high TxGNN score "likely reflects indirect graph associations (possibly via metabolic–neurological comorbidity nodes) rather than a genuine mechanistic connection," and that there is "no known mechanistic support" for this pairing. This should be read as a strong caveat rather than a positive signal — the model score is high, but the underlying biological plausibility is not established.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Australia Market Information

Semaglutide has no ARTG entries recorded in this evidence pack (0 licences; market status: Not Marketed). No dosage form or approved-indication data is available to summarise.

---

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. (Key warnings, contraindications, and DDI data are not available in this evidence pack — DDI query status: not found.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate pairing has L5 evidence (model prediction only) — zero clinical trials, zero literature, and the evidence pack's own mechanistic assessment finds no known biological connection between GLP-1 receptor signalling and the anti-GAD65 autoimmune process underlying Stiff Person Syndrome. The TxGNN score alone is insufficient to advance past screening.

**To proceed, the following is needed:**
- TGA-approved Product Information (labelling, warnings, contraindications) — currently blocking safety pre-screening (S1)
- Confirmed mechanism-of-action data for semaglutide from a primary source (e.g. DrugBank/TGA PI), rather than inference from prediction rationale text
- Preclinical or mechanistic studies establishing biological plausibility between GLP-1 agonism and autoimmune neuromuscular disease before any clinical evidence-gathering is warranted
- Confirmed original (approved) indication data, since none is currently recorded in this evidence pack

**Note:** Among the 10 candidate indications generated for semaglutide in this dataset, none currently carry clinical trial or strong literature support. The comparatively best-evidenced candidate is *pancreatic agenesis* (rank 9, L4, 3 supporting publications), though its own rationale also concludes semaglutide lacks a pharmacological basis for that condition (agenesis leaves no residual β-cell mass for a GLP-1 agonist to act on). All 10 candidates are currently scored "Hold."
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

